{"id":"https://openalex.org/W2883482938","doi":"https://doi.org/10.1002/ajh.25228","title":"Duvelisib, an oral dual PI3K\u2010\u03b4, \u03b3 inhibitor, shows clinical activity in indolent non\u2010Hodgkin lymphoma in a phase 1 study","display_name":"Duvelisib, an oral dual PI3K\u2010\u03b4, \u03b3 inhibitor, shows clinical activity in indolent non\u2010Hodgkin lymphoma in a phase 1 study","publication_year":2018,"publication_date":"2018-07-23","ids":{"openalex":"https://openalex.org/W2883482938","doi":"https://doi.org/10.1002/ajh.25228","mag":"2883482938","pmid":"https://pubmed.ncbi.nlm.nih.gov/30033575","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6220789"},"language":"en","primary_location":{"id":"doi:10.1002/ajh.25228","doi":"https://doi.org/10.1002/ajh.25228","is_oa":true,"landing_page_url":"https://doi.org/10.1002/ajh.25228","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25228","source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25228","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000959540","display_name":"Ian W. Flinn","orcid":"https://orcid.org/0000-0001-6724-290X","observed_orcids":["https://orcid.org/0000-0001-6724-290X"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ian W. Flinn","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, Tennessee","Tennessee Oncology, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210100810"]},{"raw_affiliation_string":"Tennessee Oncology, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005718112","display_name":"Manish R. Patel","orcid":"https://orcid.org/0000-0001-6836-2364","observed_orcids":["https://orcid.org/0000-0001-6836-2364"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210138011","display_name":"Oncology Specialists of Charlotte","ror":"https://ror.org/039b8pv66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210138011"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Manish Patel","raw_affiliation_strings":["Florida Cancer Specialists, Sarasota, Florida","Sarah Cannon Research Institute, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Cancer Specialists, Sarasota, Florida","institution_ids":["https://openalex.org/I4210138011"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037784199","display_name":"Yasuhiro Oki","orcid":"https://orcid.org/0000-0003-3038-4298","observed_orcids":["https://orcid.org/0000-0003-3038-4298"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yasuhiro Oki","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069406522","display_name":"Steven Michael Horwitz","orcid":"https://orcid.org/0000-0002-6399-2006","observed_orcids":["https://orcid.org/0000-0002-6399-2006"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven Horwitz","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, New York","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088820789","display_name":"Francine M. Foss","orcid":"https://orcid.org/0000-0001-7843-3162","observed_orcids":["https://orcid.org/0000-0001-7843-3162"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francine F. Foss","raw_affiliation_strings":["Yale University Cancer Center, New Haven, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale University Cancer Center, New Haven, Connecticut","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009763835","display_name":"Kerstin R. Allen","orcid":"https://orcid.org/0009-0004-9286-6158","observed_orcids":["https://orcid.org/0009-0004-9286-6158"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kerstin Allen","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074128964","display_name":"Mark Douglas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Douglas","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028575353","display_name":"Howard Marvin Stern","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard Stern","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112877054","display_name":"Jennifer Sweeney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Sweeney","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089791403","display_name":"Jahnavi Kharidia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jahnavi Kharidia","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066471470","display_name":"Patrick Francis Kelly","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Kelly","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110640745","display_name":"Virginia M. Kelly","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Virginia M. Kelly","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5069054551","display_name":"Brad S. Kahl","orcid":"https://orcid.org/0000-0003-0459-6609","observed_orcids":["https://orcid.org/0000-0003-0459-6609"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brad Kahl","raw_affiliation_strings":["Washington University, St. Louis, Missouri"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington University, St. Louis, Missouri","institution_ids":["https://openalex.org/I204465549"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5000959540"],"corresponding_institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"],"apc_list":{"value":5450,"currency":"USD","value_usd":5450},"apc_paid":{"value":5450,"currency":"USD","value_usd":5450},"fwci":3.9929,"has_fulltext":true,"cited_by_count":39,"citation_normalized_percentile":{"value":0.9411533,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"93","issue":"11","first_page":"1311","last_page":"1317"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.6758000254631042,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.6758000254631042,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.3158999979496002,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/duvelisib","display_name":"duvelisib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pi3kdelta-inhibitor","display_name":"PI3K\u03b4 inhibitor","score":0.6700000166893005},{"id":"https://openalex.org/keywords/indolent-non-hodgkin-lymphoma","display_name":"indolent non-Hodgkin lymphoma","score":0.9890000224113464},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.8610000014305115},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8960000276565552},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9419999718666077},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7480000257492065},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8740000128746033},{"id":"https://openalex.org/keywords/oral-kinase-inhibitor","display_name":"oral kinase inhibitor","score":0.5220000147819519},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.6269999742507935},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.4350000023841858}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9178605079650879},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6817702054977417},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5979390144348145},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5941983461380005},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.566140353679657},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.46385976672172546},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.4623853266239166},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.45891818404197693},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.44466838240623474},{"id":"https://openalex.org/C2777914695","wikidata":"https://www.wikidata.org/wiki/Q12192","display_name":"Pneumonia","level":2,"score":0.42329272627830505},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.25744813680648804},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000081082","descriptor_name":"Phosphoinositide-3 Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000637","descriptor_name":"Transaminases","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D005076","descriptor_name":"Exanthema","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007546","descriptor_name":"Isoquinolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007546","descriptor_name":"Isoquinolines","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D008228","descriptor_name":"Lymphoma, Non-Hodgkin","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D008228","descriptor_name":"Lymphoma, Non-Hodgkin","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008228","descriptor_name":"Lymphoma, Non-Hodgkin","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1002/ajh.25228","doi":"https://doi.org/10.1002/ajh.25228","is_oa":true,"landing_page_url":"https://doi.org/10.1002/ajh.25228","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25228","source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5177134","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC6220789","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6220789","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6220789","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Am J Hematol","raw_type":"Text"},{"id":"pmid:30033575","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30033575","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American journal of hematology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1002/ajh.25228","doi":"https://doi.org/10.1002/ajh.25228","is_oa":true,"landing_page_url":"https://doi.org/10.1002/ajh.25228","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25228","source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G9000856728","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA008748","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320307191","display_name":"Vera Bradley Foundation for Breast Cancer","ror":"https://ror.org/022897k65"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2883482938.pdf","grobid_xml":"https://content.openalex.org/works/W2883482938.grobid-xml"},"referenced_works_count":41,"referenced_works":["https://openalex.org/W83532321","https://openalex.org/W1493876987","https://openalex.org/W1648671938","https://openalex.org/W1757407923","https://openalex.org/W1963866495","https://openalex.org/W1984999956","https://openalex.org/W1995618664","https://openalex.org/W2011225907","https://openalex.org/W2012228539","https://openalex.org/W2023400811","https://openalex.org/W2026234361","https://openalex.org/W2026602389","https://openalex.org/W2029695719","https://openalex.org/W2038053631","https://openalex.org/W2046905172","https://openalex.org/W2057370954","https://openalex.org/W2070361307","https://openalex.org/W2102165558","https://openalex.org/W2102406553","https://openalex.org/W2103470187","https://openalex.org/W2105601966","https://openalex.org/W2106684817","https://openalex.org/W2123666692","https://openalex.org/W2129741568","https://openalex.org/W2133201432","https://openalex.org/W2134797116","https://openalex.org/W2134861285","https://openalex.org/W2136166312","https://openalex.org/W2150724746","https://openalex.org/W2163577434","https://openalex.org/W2169961966","https://openalex.org/W2268444447","https://openalex.org/W2293645537","https://openalex.org/W2397780009","https://openalex.org/W2471428167","https://openalex.org/W2762226752","https://openalex.org/W2763233348","https://openalex.org/W2775670706","https://openalex.org/W2885065879","https://openalex.org/W2980882408","https://openalex.org/W4245421676"],"related_works":["https://openalex.org/W2775670706","https://openalex.org/W1476088316","https://openalex.org/W2885065879","https://openalex.org/W3038563658","https://openalex.org/W2913987637","https://openalex.org/W2605943665","https://openalex.org/W2557056596","https://openalex.org/W4313585435","https://openalex.org/W2943077618","https://openalex.org/W4206726440"],"abstract_inverted_index":{"Duvelisib":[0,191],"(IPI-145)":[1],"is":[2],"an":[3,197],"oral":[4],"dual":[5],"inhibitor":[6],"of":[7,18,45,104,126,140],"phosphoinositide-3-kinase":[8],"(PI3K)-\u03b4":[9],"and":[10,43,81,90,114,124,137,161,182,196],"-\u03b3":[11],"in":[12,48,64,167,201],"clinical":[13,41,194,216],"development":[14],"for":[15,214],"the":[16,34,91,138,168],"treatment":[17],"hematologic":[19,52],"malignancies,":[20,53],"including":[21],"indolent":[22],"non-Hodgkin":[23],"lymphoma":[24],"(iNHL).":[25],"In":[26],"a":[27,65,108],"Phase":[28],"1,":[29],"open-label":[30],"study":[31],"to":[32,95,119],"determine":[33],"maximum":[35],"tolerated":[36],"dose":[37,59],"(MTD),":[38],"pharmacokinetics,":[39],"pharmacodynamics,":[40],"activity,":[42],"safety":[44,199],"duvelisib":[46,54],"monotherapy":[47],"patients":[49,106,187],"with":[50,209],"advanced":[51],"was":[55,93,121,128,134,146],"administered":[56],"at":[57,86,143],"eight":[58],"levels":[60],"(8-100":[61],"mg":[62,88,98,170,211],"BID)":[63],"dose-escalation":[66],"phase":[67],"(n":[68],"=":[69],"31":[70],"evaluable":[71],"patients).":[72],"Two":[73],"dose-limiting":[74],"toxicities":[75],"(DLTs),":[76],"Grade":[77,82],"3":[78,83],"transaminase":[79],"elevations":[80],"rash,":[84],"occurred":[85],"100":[87],"BID,":[89],"MTD":[92],"determined":[94],"be":[96],"75":[97,169],"BID.":[99],"Across":[100],"all":[101,166],"doses,":[102],"58.1%":[103],"iNHL":[105,186,207],"had":[107],"response":[109,120,127],"(19.4%":[110],"complete,":[111],"35.5%":[112],"partial,":[113],"3.2%":[115],"minor);":[116],"median":[117],"time":[118],"1.84":[122],"months":[123,145],"duration":[125],"16.9":[129],"months.":[130],"Median":[131],"progression-free":[132],"survival":[133,142],"14.7":[135],"months,":[136],"probability":[139],"overall":[141],"24":[144],"71.7%.":[147],"Severe":[148],"(Grade":[149],"\u2265":[150],"3)":[151],"adverse":[152],"events":[153],"included":[154],"elevated":[155],"liver":[156],"enzymes":[157],"(38.7%),":[158],"diarrhea":[159],"(25.8%),":[160],"neutropenia":[162],"(29.0%).":[163],"Three":[164],"patients,":[165,208],"BID":[171,212],"cohort,":[172],"experienced":[173,188],"fatal":[174],"AEs:":[175],"E.":[176],"coli":[177],"sepsis,":[178],"acute":[179],"respiratory":[180],"failure,":[181],"fungal":[183],"pneumonia.":[184,190],"No":[185],"Pneumocystis":[189],"demonstrated":[192],"favorable":[193],"activity":[195],"acceptable":[198],"profile":[200],"these":[202],"high-risk,":[203],"heavily":[204],"pretreated,":[205],"relapsed/refractory":[206],"25":[210],"selected":[213],"further":[215],"development.":[217]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-08-03T00:00:00"}